Novo Nordisk A/S (NVO) 45.90 $NVO Novo Nordisk'
Post# of 273243
Posted On: 09/08/2016 11:18:57 AM
Novo Nordisk A/S (NVO) 45.90 $NVO
Novo Nordisk's IDegLira Review Period Extended in the U.S.
Zacks Equity Research - Zacks Investment Research - Mon Sep 05, 7:31AM CDT
Novo Nordisk (NVO) announced that the FDA has extended the review period of a NDA for IDegLira for the treatment of adults with type II diabetes by three months.
NVO: 45.90 (+0.01), ANIP: 61.44 (+0.73), ANIK: 47.70 (-0.61), PCRX: 40.76 (+0.22)
FDA extends regulatory review period for IDegLira by three months
Globe Newswire - Fri Sep 02, 4:47PM CDT
Bagsvaerd, Denmark, 2 September 2016 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has extended the regulatory review period for IDegLira, the fixed-ratio combination of insulin degludec and liraglutide in adults with type 2 diabetes.
NVO: 45.90 (+0.01)
SmarTrend Watching for Potential Rebound in Shares of Novo Nordisk After 1.36% Loss
Comtex SmarTrend(R) - Fri Sep 02, 12:47PM CDT
Novo Nordisk (NYSE:NVO) traded in a range yesterday that spanned from a low of $45.36 to a high of $45.84. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $46.13 on volume of 2.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVO: 45.90 (+0.01)
Downgrade Alert for Novo Nordisk (NVO)
Comtex SmarTrend(R) - Fri Sep 02, 3:13AM CDT
Novo Nordisk (NYSE:NVO) was downgraded from Overweight to Equal Weight at Morgan Stanley today. The stock closed yesterday at $46.34 on volume of 2.8 million shares, above average daily volume of 1.0 million. Potential upside of 53.4% exists for Novo Nordisk, based on a current level of $46.34 and analysts' average consensus price target of $71.10. The stock should run into initial resistance at its 200-day moving average (MA) of $55.18 and subsequent resistance at its 50-day MA of $55.23.
NVO: 45.90 (+0.01)
Upgrade Alert for Novo Nordisk (NVO)
Comtex SmarTrend(R) - Thu Sep 01, 3:17AM CDT
Novo Nordisk (NYSE:NVO) was upgraded from Reduce to Hold at HSBC today. The stock closed yesterday at $46.72 on volume of 1.3 million shares, above average daily volume of 1.0 million. Novo Nordisk (NYSE:NVO) has potential upside of 52.2% based on a current price of $46.72 and analysts' consensus price target of $71.10. Novo Nordisk shares should first meet resistance at the 200-day moving average (MA) of $55.18 and find additional resistance at the 50-day MA of $55.23.
NVO: 45.90 (+0.01)
Lars Rebien Sorensen to retire as CEO of Novo Nordisk; Lars Fruergaard Jorgensen appointed as successor
Globe Newswire - Thu Sep 01, 1:06AM CDT
Bagsvaerd, Denmark, 1 September 2016 - Novo Nordisk A/S today announced that Lars Rebien Sorensen, president and chief executive officer, will retire from the company by the end of 2016. Lars Fruergaard Jorgensen, currently executive vice president and head of Corporate Development, will succeed him, effective 1 January 2017. The company also announced a number of other executive-level changes, effective immediately.
NVO: 45.90 (+0.01)
Sponsor and CRO Finalists Announced for Annual Society for Clinical Research Sites' Eagle Award
PR Newswire - Thu Aug 25, 9:00AM CDT
The Society for Clinical Research Sites announces today the finalists for the 2016 SCRS Eagle Award(TM). The finalists were selected from nominations provided by SCRS members. Qualifying nominees were in the 75th percentile or higher of the total nominations submitted for the Eagle Award. Voting is now open to all clinical research site professionals, regardless of their membership with SCRS, and closes September 21, 2016. Go to this website to vote.
NVO: 45.90 (+0.01), MRK: 62.93 (+0.06), AMGN: 170.73 (+0.10), LLY: 79.65 (+1.06), GSK: 43.64 (-0.18)
Look for Shares of Novo Nordisk to Potentially Pullback after Yesterday's 1.39% Rise
Comtex SmarTrend(R) - Mon Aug 22, 12:54PM CDT
Novo Nordisk (NYSE:NVO) traded in a range yesterday that spanned from a low of $47.39 to a high of $47.98. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $47.29 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NVO: 45.90 (+0.01)
Hip-Hop Legend Rev Run and Wife Justine Simmons Unveil Experiential Photo Exhibit with Novo Nordisk Depicting the Millions of Americans at Risk of Diabetes
PR Newswire - Mon Aug 15, 7:30AM CDT
Novo Nordisk today unveiled the "Am I at Risk?" traveling exhibit as an extension of its Ask.Screen.Know.® program urging adults to know their risk of type 2 diabetes at 30th Street Station in Philadelphia. Twenty-nine million Americans are living with diabetes and 1 in 4 do not know it.1 The exhibit illustrates the many different faces of Americans who are at risk of diabetes, including Ask.Screen.Know.® ambassadors Rev Run and Justine Simmons.
NVO: 45.90 (+0.01)
Emisphere Reports Second Quarter 2016 Financial Results
GlobeNewswire - Mon Aug 15, 6:30AM CDT
Emisphere Technologies, Inc. (OTCBB:EMIS) today reported financial results for the second quarter ended June 30, 2016, and provided an overview of corporate accomplishments and plans.
NVO: 45.90 (+0.01)
Top 3 Research Reports for August 12, 2016
Sheraz Mian - Zacks Investment Research - Fri Aug 12, 12:17PM CDT
Top 3 Research Reports for August 12, 2016
DFS: 59.71 (+0.17), NVO: 45.90 (+0.01), CHTR: 270.26 (-7.30), MRK: 62.93 (+0.06), PNC: 90.61 (+0.19), EQR: 64.35 (-1.37)
Goulston & Storrs Advises Hana Asset Management-Led Consortium of South Korean Investors in Acquisition of Novo Nordisk Headquarters in New Jersey
PR Newswire - Fri Aug 12, 9:58AM CDT
Goulston & Storrs is pleased to announce that the firm has advised a consortium of South Korean investors led by Hana Asset Management in its acquisition of Novo Nordisk's 762,000-square-foot North American headquarters in Plainsboro, New Jersey with an investment of $305 million. This marks the largest single-asset sale in New Jersey to date in 2016.
NVO: 45.90 (+0.01)
Hana Asset Management-Led Consortium of South Korean Investors Acquires Novo Nordisk Headquarters in New Jersey
PR Newswire - Fri Aug 12, 9:15AM CDT
Hana Asset Management has led a consortium of South Korean investors in its acquisition today of Novo Nordisk's 762,000-square-foot North American headquarters in Plainsboro, New Jersey with an investment of $305 million. This marks the largest single-asset sale in New Jersey to date in 2016.
NVO: 45.90 (+0.01)
Post Earnings Coverage as Novo Nordisk Tops Profit Expectations with 23 Percent Growth
ACCESSWIRE - Wed Aug 10, 8:15AM CDT
LONDON, UK / ACCESSWIRE / August 10, 2016 / Active Wall St. announces its post-earnings coverage on Novo Nordisk A/S (NYSE: NVO). The company released its second quarter 2016 financial results on August 5, 2016. The pharma giant reported a 19% surge in its net profit for Q2, propelled by strong sales of its new products treating diabetes and obesity. However, the company narrowed its revenue growth outlook for 2016 due to a difficult U.S. market. Register with us now for your free membership at: http://www.activewallst.com/register/.
NVO: 45.90 (+0.01)
Watch for Novo Nordisk to Potentially Rebound After Falling 4.65% Yesterday
Comtex SmarTrend(R) - Mon Aug 08, 12:00PM CDT
Novo Nordisk (NYSE:NVO) traded in a range yesterday that spanned from a low of $47.45 to a high of $47.84. Yesterday, the shares fell 4.7%, which took the trading range below the 3-day low of $48.88 on volume of 4.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVO: 45.90 (+0.01)
Novo Nordisk (NVO) Beats Q2 Earnings, Revenues Up Y/Y
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 6:53AM CDT
Novo Nordisk (NVO) reported second-quarter 2016 earnings of 60 cents per American Depository Receipt, above the Zacks Consensus Estimate earnings of 58 cents.
NVO: 45.90 (+0.01), GERN: 3.05 (unch), CORT: 5.72 (+0.01), ANIK: 47.75 (-0.56)
Novo Nordisk increased adjusted operating profit by 8% in local currencies in the first six months of 2016
Globe Newswire - Fri Aug 05, 12:30AM CDT
Sales increased by 7% in local currencies Sales increased by 7% in local currencies and by 5% in Danish kroner to DKK 54.7 billion.
NVO: 45.90 (+0.01)
Drug Manufacturers Stocks on Investors' Radar -- Synergy Pharma, Novo Nordisk, Biodel, and DURECT
PR Newswire - Thu Aug 04, 7:10AM CDT
The Drug Manufacturers segment is an intensive space that is driven by demand for medicines and related health-care products. Long-term industry outlook is positive with global sales projected to reach $1.4 trillion by 2019. Stock-Callers.com takes a look at the following companies and see what investors make of them: Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), Novo Nordisk A/S (NYSE: NVO), Biodel Inc. (NASDAQ: BIOD), and DURECT Corp. (NASDAQ: DRRX). Learn more about these stocks by downloading their comprehensive and free reports at:
SGYP: 5.07 (+0.02), NVO: 45.90 (+0.01), DRRX: 1.65 (-0.05), BIOD: 0.44 (+0.02)
Novo Nordisk's IDegLira Review Period Extended in the U.S.
Zacks Equity Research - Zacks Investment Research - Mon Sep 05, 7:31AM CDT
Novo Nordisk (NVO) announced that the FDA has extended the review period of a NDA for IDegLira for the treatment of adults with type II diabetes by three months.
NVO: 45.90 (+0.01), ANIP: 61.44 (+0.73), ANIK: 47.70 (-0.61), PCRX: 40.76 (+0.22)
FDA extends regulatory review period for IDegLira by three months
Globe Newswire - Fri Sep 02, 4:47PM CDT
Bagsvaerd, Denmark, 2 September 2016 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has extended the regulatory review period for IDegLira, the fixed-ratio combination of insulin degludec and liraglutide in adults with type 2 diabetes.
NVO: 45.90 (+0.01)
SmarTrend Watching for Potential Rebound in Shares of Novo Nordisk After 1.36% Loss
Comtex SmarTrend(R) - Fri Sep 02, 12:47PM CDT
Novo Nordisk (NYSE:NVO) traded in a range yesterday that spanned from a low of $45.36 to a high of $45.84. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $46.13 on volume of 2.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVO: 45.90 (+0.01)
Downgrade Alert for Novo Nordisk (NVO)
Comtex SmarTrend(R) - Fri Sep 02, 3:13AM CDT
Novo Nordisk (NYSE:NVO) was downgraded from Overweight to Equal Weight at Morgan Stanley today. The stock closed yesterday at $46.34 on volume of 2.8 million shares, above average daily volume of 1.0 million. Potential upside of 53.4% exists for Novo Nordisk, based on a current level of $46.34 and analysts' average consensus price target of $71.10. The stock should run into initial resistance at its 200-day moving average (MA) of $55.18 and subsequent resistance at its 50-day MA of $55.23.
NVO: 45.90 (+0.01)
Upgrade Alert for Novo Nordisk (NVO)
Comtex SmarTrend(R) - Thu Sep 01, 3:17AM CDT
Novo Nordisk (NYSE:NVO) was upgraded from Reduce to Hold at HSBC today. The stock closed yesterday at $46.72 on volume of 1.3 million shares, above average daily volume of 1.0 million. Novo Nordisk (NYSE:NVO) has potential upside of 52.2% based on a current price of $46.72 and analysts' consensus price target of $71.10. Novo Nordisk shares should first meet resistance at the 200-day moving average (MA) of $55.18 and find additional resistance at the 50-day MA of $55.23.
NVO: 45.90 (+0.01)
Lars Rebien Sorensen to retire as CEO of Novo Nordisk; Lars Fruergaard Jorgensen appointed as successor
Globe Newswire - Thu Sep 01, 1:06AM CDT
Bagsvaerd, Denmark, 1 September 2016 - Novo Nordisk A/S today announced that Lars Rebien Sorensen, president and chief executive officer, will retire from the company by the end of 2016. Lars Fruergaard Jorgensen, currently executive vice president and head of Corporate Development, will succeed him, effective 1 January 2017. The company also announced a number of other executive-level changes, effective immediately.
NVO: 45.90 (+0.01)
Sponsor and CRO Finalists Announced for Annual Society for Clinical Research Sites' Eagle Award
PR Newswire - Thu Aug 25, 9:00AM CDT
The Society for Clinical Research Sites announces today the finalists for the 2016 SCRS Eagle Award(TM). The finalists were selected from nominations provided by SCRS members. Qualifying nominees were in the 75th percentile or higher of the total nominations submitted for the Eagle Award. Voting is now open to all clinical research site professionals, regardless of their membership with SCRS, and closes September 21, 2016. Go to this website to vote.
NVO: 45.90 (+0.01), MRK: 62.93 (+0.06), AMGN: 170.73 (+0.10), LLY: 79.65 (+1.06), GSK: 43.64 (-0.18)
Look for Shares of Novo Nordisk to Potentially Pullback after Yesterday's 1.39% Rise
Comtex SmarTrend(R) - Mon Aug 22, 12:54PM CDT
Novo Nordisk (NYSE:NVO) traded in a range yesterday that spanned from a low of $47.39 to a high of $47.98. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $47.29 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NVO: 45.90 (+0.01)
Hip-Hop Legend Rev Run and Wife Justine Simmons Unveil Experiential Photo Exhibit with Novo Nordisk Depicting the Millions of Americans at Risk of Diabetes
PR Newswire - Mon Aug 15, 7:30AM CDT
Novo Nordisk today unveiled the "Am I at Risk?" traveling exhibit as an extension of its Ask.Screen.Know.® program urging adults to know their risk of type 2 diabetes at 30th Street Station in Philadelphia. Twenty-nine million Americans are living with diabetes and 1 in 4 do not know it.1 The exhibit illustrates the many different faces of Americans who are at risk of diabetes, including Ask.Screen.Know.® ambassadors Rev Run and Justine Simmons.
NVO: 45.90 (+0.01)
Emisphere Reports Second Quarter 2016 Financial Results
GlobeNewswire - Mon Aug 15, 6:30AM CDT
Emisphere Technologies, Inc. (OTCBB:EMIS) today reported financial results for the second quarter ended June 30, 2016, and provided an overview of corporate accomplishments and plans.
NVO: 45.90 (+0.01)
Top 3 Research Reports for August 12, 2016
Sheraz Mian - Zacks Investment Research - Fri Aug 12, 12:17PM CDT
Top 3 Research Reports for August 12, 2016
DFS: 59.71 (+0.17), NVO: 45.90 (+0.01), CHTR: 270.26 (-7.30), MRK: 62.93 (+0.06), PNC: 90.61 (+0.19), EQR: 64.35 (-1.37)
Goulston & Storrs Advises Hana Asset Management-Led Consortium of South Korean Investors in Acquisition of Novo Nordisk Headquarters in New Jersey
PR Newswire - Fri Aug 12, 9:58AM CDT
Goulston & Storrs is pleased to announce that the firm has advised a consortium of South Korean investors led by Hana Asset Management in its acquisition of Novo Nordisk's 762,000-square-foot North American headquarters in Plainsboro, New Jersey with an investment of $305 million. This marks the largest single-asset sale in New Jersey to date in 2016.
NVO: 45.90 (+0.01)
Hana Asset Management-Led Consortium of South Korean Investors Acquires Novo Nordisk Headquarters in New Jersey
PR Newswire - Fri Aug 12, 9:15AM CDT
Hana Asset Management has led a consortium of South Korean investors in its acquisition today of Novo Nordisk's 762,000-square-foot North American headquarters in Plainsboro, New Jersey with an investment of $305 million. This marks the largest single-asset sale in New Jersey to date in 2016.
NVO: 45.90 (+0.01)
Post Earnings Coverage as Novo Nordisk Tops Profit Expectations with 23 Percent Growth
ACCESSWIRE - Wed Aug 10, 8:15AM CDT
LONDON, UK / ACCESSWIRE / August 10, 2016 / Active Wall St. announces its post-earnings coverage on Novo Nordisk A/S (NYSE: NVO). The company released its second quarter 2016 financial results on August 5, 2016. The pharma giant reported a 19% surge in its net profit for Q2, propelled by strong sales of its new products treating diabetes and obesity. However, the company narrowed its revenue growth outlook for 2016 due to a difficult U.S. market. Register with us now for your free membership at: http://www.activewallst.com/register/.
NVO: 45.90 (+0.01)
Watch for Novo Nordisk to Potentially Rebound After Falling 4.65% Yesterday
Comtex SmarTrend(R) - Mon Aug 08, 12:00PM CDT
Novo Nordisk (NYSE:NVO) traded in a range yesterday that spanned from a low of $47.45 to a high of $47.84. Yesterday, the shares fell 4.7%, which took the trading range below the 3-day low of $48.88 on volume of 4.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVO: 45.90 (+0.01)
Novo Nordisk (NVO) Beats Q2 Earnings, Revenues Up Y/Y
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 6:53AM CDT
Novo Nordisk (NVO) reported second-quarter 2016 earnings of 60 cents per American Depository Receipt, above the Zacks Consensus Estimate earnings of 58 cents.
NVO: 45.90 (+0.01), GERN: 3.05 (unch), CORT: 5.72 (+0.01), ANIK: 47.75 (-0.56)
Novo Nordisk increased adjusted operating profit by 8% in local currencies in the first six months of 2016
Globe Newswire - Fri Aug 05, 12:30AM CDT
Sales increased by 7% in local currencies Sales increased by 7% in local currencies and by 5% in Danish kroner to DKK 54.7 billion.
NVO: 45.90 (+0.01)
Drug Manufacturers Stocks on Investors' Radar -- Synergy Pharma, Novo Nordisk, Biodel, and DURECT
PR Newswire - Thu Aug 04, 7:10AM CDT
The Drug Manufacturers segment is an intensive space that is driven by demand for medicines and related health-care products. Long-term industry outlook is positive with global sales projected to reach $1.4 trillion by 2019. Stock-Callers.com takes a look at the following companies and see what investors make of them: Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), Novo Nordisk A/S (NYSE: NVO), Biodel Inc. (NASDAQ: BIOD), and DURECT Corp. (NASDAQ: DRRX). Learn more about these stocks by downloading their comprehensive and free reports at:
SGYP: 5.07 (+0.02), NVO: 45.90 (+0.01), DRRX: 1.65 (-0.05), BIOD: 0.44 (+0.02)
(0)
(0)Scroll down for more posts ▼